INITIAL PUBLIC OFFERINGS:Biotech IPOs Cool Amid Market Jitters
As public market enthusiasm wavers, companies going public face tougher terms.
Biotech IPOs have cooled considerably since the selloff of biotech stocks that began March 21. The two biotechs that went public on U.S. exchanges during the second week of April met with a muted reception by investors growing wary of a biotech bubble. Read More